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Accepted 6 August 2010Cerebrospinal fluid (CSF) biomarkers are nowwidely used for diagnosis of Alzheimer disease
(AD) in atypical clinical forms, for differential and early diagnosis, or for stratification of
patients in clinical trials. Among these biomarkers, different forms of amyloid peptides (Aβ)
produced by the cleavage of a transmembrane precursor protein called APP (amyloid
precursor protein) have amajor role. Aβ peptides exist in different length themost common
ones having 40 (Aβ40), 42 (Aβ42), or 38 (Aβ38) amino acids in length. APP processing by
gamma-secretase releases also an amino-terminal secreted fragment called sAβPP-beta
while an alternative nonamyloidogenic cleavage of APP, through an alpha-secretase,
liberates another fragment called sAβPP-alpha. To decipher the molecular and pathological
mechanisms leading to the production and the detection of these entities is essential for the
comprehension and the prevention of AD. In this report, we present the results of theKeywords:
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and 42 in human cerebrospinal fluid, Brmultiplex measurement of CSF Aβ38, Aβ40, Aβ42, sAβPP-alpha, and sAβPP-beta in 60
patients mostly with dementia eventually segregated between neurochemical dementia
diagnostic (NDD) positive and negative groups. The NDD classification was based on our
routine Tau, P-tau181, and Aβ42 cutoff values. We confirmed previous findings regarding the
correlation between sAβPP-alpha and sAβPP-beta, as well as the potential interest of these
new biomarkers. We also studied the correlation between sAβPPs and Aβ peptides, as well
as between Aβ peptides themselves. We observed a strong correlation between Aβ38 and
sAβPP-beta which suggested that the production of this peptide was in direct relation with β
secretase activities. We also reported a strong correlation between Aβ38 and Aβ40, while
Aβ42 was correlated to these fragments only in nonpathological situations. These results
enlighten the complex relationships between thesemolecularmarkers in both physiological
and pathological situations. Our results are important for the further use of these analytes
for AD diagnosis as well as for validating the cell biological hypotheses of APP processing
and Aβ fragment production.
© 2010 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer disease (AD) is a neurodegenerative disorder
characterized by significant cognitive deficits, language trou-
bles, behavior changes and loss of functional autonomy. As
the major cause of dementia in the elderly population, AD is
approaching epidemic proportions in the Western industrial-
ized countries due to aging of the population. AD is becoming a
major public health issue with the increasing burden on
caregivers and on the health care system. AD characteristic
neuropathological lesions are represented by amyloid plaques
and neurofibrillary tangles which coexist in the brain. The
diagnosis of AD based on clinical, neuropsychological, mor-
phological, as well as functional neuroimaging can remain
dubious in a considerable number of cases delaying the
diagnosis and the medical care. These data are already
powerful but lead only to probability diagnosis. Recent new
sets of diagnosis criteria including specific morphological
(volumetric MRI), functional imagery (PET scan), and CSF
biomarkers (total and phosphorylated Tau (P-tau) proteins and
Aβ peptides) have been proposed to optimize the diagnosis
(Dubois et al., 2007). When comparing AD patients to healthy
controls, CSF concentrations of Tau and P-tauwere reported to
be increased, while Aβ1–42 levels were decreased (Blennow
and Hampel, 2003). Numerous studies have analysed the
potential of CSF biomarkers in terms of positive diagnosis,
differential diagnosis, and prognosis as predictive marker of
the conversion (mild cognitive impairment (MCI) to AD)
(Gabelle et al., 2009; Herukka et al., 2007; Mattsson et al.,
2009). In combination and using several published ratios,
these biomarkers reached a sensitivity and specificity for
positive AD diagnosis beyond 80% (Ibach et al., 2006). We
obtained similar results in our routine practice on more than
350 patients (unpublished results) using as cutoff values for
P-tau and IATI (Innogenetics Aβ/Tau index), 60 and 0.8,
respectively. The future development of therapeutic strategies
aiming at slowing down or even blocking the neurodegener-
ative process could however benefit from earlier and more
sensitive diagnosis AD biomarkers.
Recently, Lewczuk et al. (2010) brought to light the interest
of CSF soluble amyloid precursor proteins (sAPP) as novel
potential biomarkers in the positive diagnosis of AD. sAPPs arel., Correlations between
ain Res. (2010), doi:10.10generated from APP following α and β cleavages (Kang et al.,
1987). The nonamyloidogenic pathway that cleaves off APP in
position α (within the sequence corresponding to Aβ) leads to
the α-secretase-cleaved soluble APP (sAPPα) fragment. The β-
secretase action on APP leads to the β-secretase-cleaved
soluble APP (sAPPβ). This β-secretase activity (BACE), com-
bined with γ-secretase cleavages releases the three major
peptide fragments Aβ40, Aβ42, and Aβ38 (Wiltfang et al., 2002)
in a kinetics that is not yet fully elucidated. It is well known
that most of the secreted Aβ fragments correspond to Aβ40,
however, in AD, a prominent pathogenic role is given to Aβ42
that aggregates muchmore rapidly due to the presence of two
additional hydrophobic amino acids, and represents the main
constituent of senile plaques (Iwatsubo et al., 1994). While
investigating presenilin mutations and γ-secretase inhibitors,
Page et al. (2008) observed that while Aβ42 and Aβ40
productions were strongly related, Aβ38 generation by γ-
secretase was not dependent on the previous entities.
The objective of the current study was to investigate the
relationship between sAPPs and Aβ fragments in different
pathophysiological contexts. Our results confirmed the po-
tential interest of sAPPs as AD biomarkers and provide
important information on the complex correlation between
the production of Aβ fragments and sAPPs.2. Results
2.1. sAPPα/β correlation and values in NDD groups
A significant correlation (Fig. 1A; r=0.87, P<0.0001) was
observed between the values of sAPPα and sAPPβ in our
population, independently of the NDD biological status. When
concentration of the biomarkers were compared betweenNDD
groups, higher mean values were obtained in NDD+(Figs. 1B
and C) with a difference with NDD− significant for sAPPβ.
These results were reminding of those of Lewczuk et al. (2010)
who analyzed a larger population and therefore obtained dif-
ferences with lower P values.
The potential interest of sAPPs for dementia diagnosis
could not be fully investigated in the present study thatsoluble α/β forms of amyloid precursor protein and Aβ38, 40,
16/j.brainres.2010.08.022
Fig. 1 – (A) Correlation between soluble amyloid precursor
protein α (sAPPα) and soluble amyloid precursor protein β
(sAPPβ) in cerebrospinal fluid (CSF) samples in whole
population (patients with neurochemical dementia
diagnostic (NDD) positive and negative results). A statistically
significant correlation was observed with r=0.87 and
P<0.001. (B and C) Comparison of the CSF sAPPα/β
concentrations between the NDD+and the NDD− groups. A
difference in mean concentration was observed and was
significant for sAPPβ (P=0.0160).
3B R A I N R E S E A R C H X X ( 2 0 1 0 ) X X X – X X Xfocused on the relationship between CSF biological values.
However, receiver operating characteristic (ROC) curve of
sAPPs for NDD+resulted in cutoff values with sensitivity of
68.2% and specificity of 57.9% for sAPPα and 81.8% and 63.2%
for sAPPβ. As illustrated Table 1, MMS status was differentPlease cite this article as: Gabelle, A., et al., Correlations between
and 42 in human cerebrospinal fluid, Brain Res. (2010), doi:10.10between NDD+and NDD− while no significant difference was
observed for the age or the CSF total protein content.
2.2. Correlation between sAPPα/β and Aβ38, 40, and 42
Correlations between sAPPα/β and Aβ38, 40, and 42 were
plotted, and Spearman factors were calculated for each pair of
biomarkers (Fig. 2). Interestingly, we observed for the first time
to our knowledge a positive correlation between sAPPs and
Aβ38 or Aβ40 independently of the NDD status. This was
particularly significant for sAPPβ and Aβ38 (r=0.72, P<0.0001)
as well as for sAPPα and Aβ38 which was unexpected as this
sAPP fragment is not generated in the same processing
pathway as Aβ peptides. The significance of sAPP correlation
was however lower with Aβ40 than with Aβ38 and was not
significant at all with Aβ42 (compare Figs. 2 AD, BE, and CF). As
Aβ42 and in a lesser extend Aβ40 are involved in AD
pathogenesis and CSF levels of these biomarkers are known
to be modified in the disease (Blennow and Hampel, 2003), the
analysis was restricted to the NDD− group (Fig. 3). This
resulted in an increase in correlation factors and a statistically
significant correlation also between sAPPs and Aβ42.
2.3. Correlation between Aβ38, 40, and 42
Correlation between the levels of Aβ38, 40, and 42 were
plotted, and Spearman factors were calculated for each pair of
biomarkers (Figs. 4A, B, and C). Interestingly, we observed that
Aβ38 and Aβ40 were strongly correlated (r=0.90, P<0.0001).
There was no correlation with Aβ42 in the total population;
however, when correlation was restricted to the NDD− group
(Fig. 4D), the correlation factor increased and was statistically
significant for Aβ38 and Aβ42.3. Discussion
In this report, we present in a series of neurochemical dementia
diagnostic (NDD) positive and negative CSF samples the results
of multiplex assays for soluble forms of amyloid precursor
proteins (sAPPs) and Aβ peptides. Data were collected in two
independent laboratories using similar and controlled preana-
lytic and analytic conditions (Lehmann et al., 2009).
Importantly, a recent investigation on sAPPα and Aβ CSF
levels already confirmed the specificity of the detection assays
used in the present study (Lewczuk et al., 2010). This previous
work revealed a surprising correlation between these two
entities. We independently confirmed this correlation (Fig. 1)
which was intriguing because it did not correspond to what
would be intuitively expected. One could believe in fact that
the production of sAPPβ would be inversely proportional to
that of sAPPα since their metabolic pathways are exclusive.
Moreover, these fragments have opposite impact (toxic vs.
neuroprotective). To our knowledge, no precise metabolic regu-
lation has beendemonstrated between α andβAPP cleavages in
the literature, and further studies would be needed to explain
this positive correlation.
We also observed a slight increase in sAPP levels in NDD+
samples compared to NDD− with a statistically significantsoluble α/β forms of amyloid precursor protein and Aβ38, 40,
16/j.brainres.2010.08.022
Table 1 – Demographic and biologic data of the NDD groups.
MMS Age CSF Total Protein
NND+ 16.4 ± 6.4 66.5 ± 7.9 0.40 ± 0.19
NND− 21.5 ± 6.3 67.3 ± 11.3 0.41 ± 0.14
P value <0.01 0.730 0.917
4 B R A I N R E S E A R C H X X ( 2 0 1 0 ) X X X – X X Xdifference only for sAPPβ (Fig. 1; P<0.02). A higher level of
sAPPβ in patients has been previously described (Lewczuk
et al., 2010) but is still controversial (Hock et al., 1998; Lannfelt
et al., 1995; Olsson et al., 2003; Palmert et al., 1990; Zetterberg
et al., 2008). In previous studies, for example, no significant
increase of sAPP usingWestern Blotting or sandwich enzyme-Fig. 2 – Correlation plots between CSF soluble amyloid precursor
(C, F) peptides in thewhole population. A statistically significant c
Please cite this article as: Gabelle, A., et al., Correlations between
and 42 in human cerebrospinal fluid, Brain Res. (2010), doi:10.10linked immunosorbent assay has been observed in AD pa-
tients (Olsson et al., 2003; Sennvik et al., 2000). In familial AD,
symptomatic patients with APP mutations had lower sAPPα
(Lannfelt et al., 1995) and low levels of this fragment were
correlated to poor performance on neuropsychological tests
(Almkvist et al., 1997). This discrepancy with recent data,proteinα/β (sAPPα/β) and Aβ38 (A, D), Aβ40 (B, E), and Aβ42
orrelationwas present only for Aβ38 andAβ40 (A, B, D, and E).
soluble α/β forms of amyloid precursor protein and Aβ38, 40,
16/j.brainres.2010.08.022
Fig. 3 – Correlation plots between CSF soluble amyloid precursor protein α/β (sAPP α/β) and Aβ40 (A, C) and Aβ42 (B, D)
peptides in the NDD− population. A statistically significant correlation was present in particular for sAPPβ and Aβ40 (C).
5B R A I N R E S E A R C H X X ( 2 0 1 0 ) X X X – X X Xincluding our, might be related to differences in population
number, preanalytics or analytical methods. In addition, we
lacked here a cognitively healthy control group which would
be needed to really evaluate the clinical interest and relevance
of sAPP measurement. In any case, a higher concentration of
sAPP in neurochemical pathological group could be explained
by several hypotheses. Firstly, the intrinsic amount of APP
available for metabolic processing could be increased in
patients with symptomatic or asymptomatic AD amyloid
lesions. This hypothesis is supported by the observation
from Lewczuk et al. (2010) that sAPPs were higher in MCI/
NDD+than in MCI/NDD− and that no significant difference
has been detected between MCI/NDD+and AD/NDD+. This
infers that pathological processes and neurochemical altera-
tions precede clinical symptoms by several years, giving
rational for the use of CSF sAPP biomarkers. It was not the
purpose of our study, which focussed on biological data, to
evaluate the interest of sAPPβ for AD diagnosis. However, with
an optimal cutoff, a sensitivity of 78.6% and a specificity of
62.5% were observed for the positive diagnosis of AD, the area
under the ROC curve being at 0.68.
One explanation for our data could be related to a feed back
regulation of APP level by Aβ concentrations. As soluble Aβ42
levels decrease in AD this could result in a positive production
signal for APP and/or for secretase activities as observed for
BACE1 in patients with AD andMCI/AD (Blennow, 2005; Zhong
et al., 2007). Finally, a modification of the degradation/
clearance of theses sAPP fragments in AD could also account
for our results.Please cite this article as: Gabelle, A., et al., Correlations between
and 42 in human cerebrospinal fluid, Brain Res. (2010), doi:10.10The second major outcome of our study relates to the
intricate relationship between sAPP fragments and Aβ peptide
levels in humanCSF. A strong correlationwas indeed observed
between Aβ38 and sAPPβ and, in a lesser extent, with sAPPα or
with Aβ40 (Fig. 2). This suggested that Aβ38 production was in
direct relation with β secretase activity even in pathological
situations. This result was of high interest with in mind the
follow-up of the activity of the β-secretase in therapeutic
strategies targeting this metabolic pathway. sAPPα and β
being correlated, it made sense to also find a limited
correlation between Aβ38 and sAPPα. Noteworthy, the corre-
lation of sAPPβwith Aβ40 and Aβ42 was really significant only
in NND− samples (Fig. 3). One interpretation of theses data is
that the three peptides were physiologically generated in
parallel through the normal processing of APP. In the presence
of an amyloid process like AD, the peptides would have
different fates. Aβ42 that is particularly prone to aggregation
would therefore have its concentration modified in the
disease (Blennow et al., 2006). The differential behaviour of
the different Aβ species was also illustrated by the strong
correlation existing in all situations between Aβ38 and Aβ40
(Fig. 4), while Aβ42 was correlated to these fragments only in
non pathological situations (NDD−). These results are impor-
tant for hypothesis on APP processing and pathologic involve-
ment. They suggest a strong physiological coregulation
between the generations of the different Aβ entities which
are all produced by the same secretase (Vassar et al., 1999).
This argued also against a nonspecific degradation/conversion
of the longer Aβ peptides into the smaller ones. The decreasesoluble α/β forms of amyloid precursor protein and Aβ38, 40,
16/j.brainres.2010.08.022
Fig. 4 – (A–D) Correlation plots between CSF Aβ38, Aβ40, and Aβ42 peptides. A strong correlation was observed in the
whole population between Aβ38 and Aβ40 (A), while the correlation between Aβ38 and Aβ42 (D) was significant only in
NDD− patients.
6 B R A I N R E S E A R C H X X ( 2 0 1 0 ) X X X – X X Xof Aβ42 observed in NDD+patients (that have also increased
P-tau levels) illustrated thestrong involvementof thispeptide in
thepathology and the loss of correlationwith the other peptides
in presence of neuropathological changes. Our observations
contribute to the biochemical rational for using ratio between
Aβ42 and Aβ40 (or Aβ38) to improve AD diagnosis (Welge et al.,
2009; Wiltfang et al., 2007). In fact, as the baseline level of Aβ
production seems variable between individuals leading to
possiblemisdiagnosis, the fact that Aβ fragments have different
fates allows using ratios independently of baseline production.
In conclusion, our correlations between sAPPs and Aβ
peptides, as well as between Aβ peptides themselves enlight-
ened the complex relationships between these molecular
markers in both physiological and pathological situations. Our
results are important for the further use of these analytes for
AD diagnosis, as well as to validated cell biological hypotheses
of APP processing and Aβ fragment production.4. Experimental procedures
4.1. Subjects and study design
Patients included in this study were selected in two indepen-
dent cohorts of subjects referring to the Neurological Units ofPlease cite this article as: Gabelle, A., et al., Correlations between
and 42 in human cerebrospinal fluid, Brain Res. (2010), doi:10.10Montpellier/Nimes and Lyon for cognitive or behavioural
troubles andwho gave their consent to include their biological
samples into a research biobanks in the field of dementia. All
patients underwent a standardized clinical and paraclinical
investigations including anamnestic, physical and neurolog-
ical examination, screening laboratory tests, neuropsycholog-
ical assessment, brain morphological imaging (CT or MRI) or
functional imaging (SPECT) evaluations, and also CSF Tau, P-
tau181, and Aβ42 analyses using Innogenetics™ ELISA kits.
All the clinical diagnoses (38 NDD−=26 DFT, 3 DCL, 7 DTA, 1
psy, and 1 other and 22 NDD+=1 DFT and 21 DTA) were
validated an expert in the field of dementia and during
consensus multidisciplinary evaluation. For AD, diagnosis
criteria of the National Institute of Neurological Disease and
Communicative Disorders and Stroke/Alzheimer's Disease
and Related Disorders Association (NINCDS/ADRDA)
(McKhann et al., 1984) were used. For frontotemporal lobar
dementia (FTD), the diagnosis criteria were based on the Lund
andManchester criteria established in 1994 (Groups, 1994) and
revised by McKhann et al. (2001) and Neary et al. (2005). The
patients with Lewy body dementia were validated using the
international clinical diagnosis consensus criteria (McKeith et
al., 2005). The diagnosis status of the patients was discussed
and confirmed during a multidisciplinary evaluation integrat-
ing imagery and clinical/neuropsychological data. Sixty CSF
samples with possible and probable AD (n=28), FTD (n=27),soluble α/β forms of amyloid precursor protein and Aβ38, 40,
16/j.brainres.2010.08.022
7B R A I N R E S E A R C H X X ( 2 0 1 0 ) X X X – X X XLBD (n=3), and other neurological disease (n=2) were ana-
lyzed. As the purpose of the investigation was primarily the
biological relationships between the studied analytes, rather
than their diagnosis interest, the samples were divided as in
Lewczuk et al. (2010) between neurochemical dementia
diagnosis-positive (NDD+) and negative (NDD−) using our
routine P-tau and IATI (Innogenetics Aβ/Tau index) cutoff
values of 60 and 0.8, respectively. A total of 22 samples
complied with NDD+conditions, the 38 remaining being in the
NDD− group.
4.2. CSF samples and routine assays
Lumbar puncture (LP) was performed in standardized condi-
tions. LP was carried out at the L3/L4 or L4/L5 interspace after
exclusion of the potential contraindications. CSF samples
were taken directly in similar polypropylene tubes to avoid
variation in adsorption of biomarkers to the container surface.
All samples were transferred to the biochemical laboratories
(CHU Montpellier/Nimes, Hospices Civils de Lyon) in less than
4 hours. The CSF was centrifuged (1000×g, 10 min, at 4–8 °C,
without break), and the supernatant was aliquoted by 0.5 mL
in polypropylene tubes before storage at −80 °C. The three
routine CSF biomarkers Tau, P-tau181, and Aβ42 were deter-
mined with a standardized commercially available ELISA Kit
(Innotest beta-amyloid 1–42 (Vanderstichele et al., 2000),
Innotest hTau-Ag (Vandermeeren et al., 1993), and Innotest
Phosphotau(181P) (Vanmechelen et al., 2000), Innogenetics,
Ghent, Belgium) in both laboratories. Quality control program
organised by Hospices Civils de Lyon was used to study inter
laboratories variability, using two CSF samples. The IATI score
was calculated using the formula IATI=Aβ42/ (240+1.18×tau)
as described (Hulstaert et al., 1999). Routine CSF analyses
included glucose, total protein and cytology. Only samples
that were assessed as red cells count <2000/mm3 were used
for analyses.
4.3. Multiplex assays of CSF sAPPα/β and Aβ38, Aβ40,
Aβ42
Detection of these analytes was performed independently in
the two laboratories using multiplex kits purchased from
Meso Scale Discovery (ref: K11120E, K11148E). All reagents
were provided with the kits. They contained a 96-well plate
with two carbon electrodes precoated with either anti APP
antibody 22C11 (sAPPα/β) or antibodies specific for Aβ38,
Aβ40, Aβ42. The wells were incubated for 1 hour with the
block solution (bovine serum albumin) and washed four times
with the TrisWash Buffer (TWB). For sAPPs duplex assay, 25 μl
of standards (dilution of recombinant sAPPs) and samples
were then added to all wells, and the plate was sealed and
incubated for 1 hour at room temperature on an orbital shaker
(300 rpm). At the end of the incubation, the wells were washed
four times using the TWB. Detection antibody (sAPPα/β) was
added at 25 μl perwell, and the plate was sealed and incubated
for 1 hour at room temperature on an orbital shaker (300 rpm).
For Aβ triplex assay, 25 μl of standards (dilution of recombi-
nant Aβ) and sampleswere added at the same time of addition
of 25 μl of detection antibody (6E10) to all wells, and the plates
were incubated during 2 hours. At the end of the incubation,Please cite this article as: Gabelle, A., et al., Correlations between
and 42 in human cerebrospinal fluid, Brain Res. (2010), doi:10.10the plate was washed four times as before. About 150 μl of the
MSD Read Buffer T was added to eachwell, and theMSD plates
were measured on the MSD Sector Imager 6000 plate reader.
The raw data were measured as electrochemiluminescence
signal (light) detected by photodetectors and analysed using
the Discovery Workbench 3.0 software (MSD). A 4-parameter
logistic fit curve was generated for each analyte using the
standards and the concentration of each sample calculated.
The intra-assay coefficient of variation ranged from 0.2% to
15.9%. The interlaboratory coefficient of variation ranged from
0.3% to 17%.
4.4. Statistical analysis
If not stated otherwise, the results were presented asmedians
and interquartile ranges. The Mann–Whitney–Wilcoxon test
was used to test the significance of the difference between two
sample groups. Correlations between measured values were
analyzedwith Spearman's correlation factor. Differences were
considered significant if P<0.05. Analyses were performed
with MedCalc (3.0).Acknowledgments
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